达洛胺:转移性激素敏感前列腺癌的综述
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Targeted oncology
|August 5, 2023
概括
达洛胺在与标准治疗相结合时,显著改善了转移性激素敏感前列腺癌的男性的整体存活率. 这种口服雄激素受体抑制剂显示出可管理的安全性,扩大了治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 转移性激素敏感前列腺癌 (mHSPC) 仍然是一个重大的临床挑战.
- 雄激素受体抑制剂 (ARi) 在控制前列腺癌进展方面至关重要.
- 现有的mHSPC治疗模式通常涉及组合疗法.
研究的目的:
- 评估达罗胺 (NUBEQA®) 与雄激素剥夺疗法 (ADT) 和mHSPC的多塞结合的疗效和安全性.
- 在一个关键试验中评估达罗胺对整体存活率和二次终点的影响.
- 为了确定达罗胺在添加到ADT和多塞塔塞尔时的耐受性概况.
主要方法:
- 一个关键的临床试验比较达洛胺加ADT和多塞与安慰剂加ADT和多塞.
- 主要终点侧重于整体存活率.
- 对二次终点和不良事件的评估,以评估治疗结果和安全性.
主要成果:
- 与安慰剂相比,达洛胺加ADT和多塞塔克塞尔在延长整体生存时间方面表现出优越性.
- 在大多数次要终点中观察到改善,表明更广泛的临床益处.
- 组合疗法表现出可管理的耐受性概况,与已知的ADT和多塞素安全性一致.
结论:
- 达洛胺为mHSPC的治疗武器库提供了一个有价值的补充.
- 这种药物看起来很有前途,特别是对于患有高体积疾病的患者.
- 使用达洛胺的扩大治疗选择增强了mHSPC的治疗策略.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K